系统性硬化症相关纤维化肌病:治疗反应与临床结局
本研究回顾性分析16例约翰霍普金斯硬皮病中心注册库中经组织病理学证实为纤维化肌病的系统性硬化症患者,评估其临床特征、治疗反应及死亡率。结果显示56.3%患者肌力显著改善,但平均随访5.5年后50%患者死亡,心肺部死因占半数。提示该亚型死亡率高,早期识别与治疗可能改善肌力。
要点
- 系统性硬化症相关纤维化肌病为独立实体,队列死亡率高。
- 56.3%患者治疗后6-12个月肌力显著改善。
- 常见治疗包括静脉免疫球蛋白、霉酚酸酯和利妥昔单抗。
核心结论
- 系统性硬化症相关纤维化肌病与高死亡率相关,早期识别并启动治疗对肌力改善具有重要意义。
研究设计与样本
- 回顾性研究,纳入约翰霍普金斯硬皮病中心研究注册库中16例经组织病理学证实为纤维化肌病的系统性硬化症患者。
主要发现
- 14/16例(87.5%)接受针对肌肉疾病的治疗,治疗后6-12个月评估肌力,9/16例(56.3%)显著改善,4/16例(25%)无显著改善,3/16例(18.8%)随访不足。
- 平均随访5.5±4.7年,8/16例(50%)死亡,其中心肺原因死亡占4/8例(50%)。
- 基线CK中位值97 U/L(四分位距46-300 U/L);14/15例(93.3%)肌电图显示肌病性改变,11/12例(91.7%)MRI显示肌肉水肿。
- 组织病理学 notable 发现为9/16例(56.3%)存在束周区域肌纤维萎缩。
临床怎么用
- 对系统性硬化症患者应警惕纤维化肌病,早期识别并启动免疫治疗可能改善肌力。
局限性
- 回顾性研究,样本量小(16例),部分患者随访不足,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the clinical features, treatment response, and mortality of patients with systemic sclerosis (SSc) associated fibrosing myopathy. METHODS: In this retrospective study, we identified patients enrolled in the Johns Hopkins Scleroderma Center Research Registry with histopathological evidence of fibrosing myopathy. Data were collected regarding SSc features, treatment exposures, and outcomes. Muscle involvement was characterized using muscle enzyme levels, muscle magnetic resonance imaging (MRI) findings, electromyography (EMG) data, and histopathologic features. RESULTS: 16 patients were included in the analysis. 14/16 patients (87.5%) received treatment specifically for muscle disease. Response based on muscle strength testing was evaluated at 6-12 months after treatment initiation. 9/16 patients (56.3%) had significant improvement, 4/16 (25%) showed no significant improvement, and 3/16 (18.8%) had inadequate follow-up. The most commonly used treatments were intravenous immunoglobulin, mycophenolate, and rituximab. After a mean follow-up time of 5.5 ± 4.7 years, 8/16 patients (50%) were deceased, with a cardiopulmonary cause of death in 4/8 (50%) of these patients. The baseline median CK value was 97 U/L (interquartile range 46-300 U/L). Myopathic changes were identified in 14/15 patients (93.3%) who had an EMG performed, while muscle edema was identified in 11/12 patients (91.7%) who underwent an MRI. A notable histopathological finding was myofiber atrophy in the perifascicular region in 9/16 patients (56.3%). CONCLUSION: SSc-associated fibrosing myopathy is a distinct entity associated with a high mortality rate in our cohort of patients. Early recognition and initiation of treatment is important due to the potential for improvement in muscle strength.
引用
- Cameron S, Mohassel P, Shah AA, et al. Fibrosing myopathy in systemic sclerosis: Treatment response and clinical outcomes in a distinct subset. Semin Arthritis Rheum. 2026. PMID: 42378828. doi:10.1016/j.semarthrit.2026.153024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。